Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
Open Access
- 11 October 2022
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (12) , bvac155
Abstract
Context Despite several reports of familial partial lipodystrophy (FPLD) type 2 (FPLD2) due to heterozygous LMNA variants and FPLD3 due to PPARG variants, the phenotypic differences among them remain unclear. Objective To compare the body fat distribution, metabolic parameters, and prevalence of metabolic complications between FPLD3 and FPLD2. Methods A retrospective, cross-sectional comparison of patients from 2 tertiary referral centers—UT Southwestern Medical Center and the National Institute of Diabetes and Digestive and Kidney Diseases. A total of 196 females and 59 males with FPLD2 (age 2-86 years) and 28 females and 4 males with FPLD3 (age 9-72 years) were included. The main outcome measures were skinfold thickness, regional body fat by dual-energy X-ray absorptiometry (DXA), metabolic variables, and prevalence of diabetes mellitus and hypertriglyceridemia. Results Compared with subjects with FPLD2, subjects with FPLD3 had significantly increased prevalence of hypertriglyceridemia (66% vs 84%) and diabetes (44% vs 72%); and had higher median fasting serum triglycerides (208 vs 255 mg/dL), and mean hemoglobin A1c (6.4% vs 7.5%). Compared with subjects with FPLD2, subjects with FPLD3 also had significantly higher mean upper limb fat (21% vs 27%) and lower limb fat (16% vs 21%) on DXA and increased median skinfold thickness at the anterior thigh (5.8 vs 11.3 mm), calf (4 vs 6 mm), triceps (5.5 vs 7.5 mm), and biceps (4.3 vs 6.8 mm). Conclusion Compared with subjects with FPLD2, subjects with FPLD3 have milder lipodystrophy but develop more severe metabolic complications, suggesting that the remaining adipose tissue in subjects with FPLD3 may be dysfunctional or those with mild metabolic disease are underrecognized.Keywords
Funding Information
- National Institutes of Health (R01-DK105448, UL1TR001105)
- National Center for Advancing Translational Sciences
- National Institutes of Health
This publication has 54 references indexed in Scilit:
- Lamin A tail modification by SUMO1 is disrupted by familial partial lipodystrophy–causing mutationsMolecular Biology of the Cell, 2013
- Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C)Diabetologia, 2011
- Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino‐terminal heterozygous missense lamin A/C mutationsClinical Genetics, 2010
- Post‐mortem findings in Dunnigan‐type familial partial lipodystrophyDiabetic Medicine, 2010
- Diseases of the Nuclear EnvelopeCold Spring Harbor Perspectives in Biology, 2010
- Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANESPLOS ONE, 2009
- Fat and Beyond: The Diverse Biology of PPARγAnnual Review of Biochemistry, 2008
- Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistanceCell Metabolism, 2006
- Acquired and Inherited LipodystrophiesNew England Journal of Medicine, 2004
- LMNA, encoding lamin A/C, is mutated in partial lipodystrophyNature Genetics, 2000